Merck & Co. (MRK)
(Delayed Data from NYSE)
$129.37 USD
-0.83 (-0.64%)
Updated Jun 13, 2024 04:00 PM ET
After-Market: $129.35 -0.02 (-0.02%) 7:18 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Brokerage Reports
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 381 - 396 ( 396 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter EPS Ahead of Expectations. Less Cost Cutting Likely Going Forward.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Second Quarter Pro-forma Revenue Down 1%. More Revenue Headwinds in the 2010 Second Half.
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Fourth Quarter Figures Reflect a Partial Quarter of Results from Schering-Plough
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S